OncoMatch/Clinical Trials/NCT06208462

Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Is NCT06208462 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Lenvatinib for intrahepatic cholangiocarcinoma.

Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical UniversityNCT06208462Data as of May 2026

Treatment: Adebrelimab · Lenvatinib · Gemcitabine · Oxaliplatin — Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cholangiocarcinoma

Disease stage

Required: Stage IB, II, III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: systemic therapy

Exception: biliary drainage allowed

Prior systemic therapy and tumor-related surgical treatment (biliary drainage allowed)

Cannot have received: PD-1 antibody

have received PD1 antibody

Cannot have received: PD-L1 antibody

have received PDL1 antibody

Cannot have received: CTLA-4 antibody

have received CTLA4 antibody

Cannot have received: VEGFR inhibitor (lenvatinib)

have received Lenvatinib

Cannot have received: chemotherapy

have received ... chemotherapy in the past

Lab requirements

Blood counts

Neutrophils ≥1.5*10^9/L; Platelet ≥80*10^9/L; Hemoglobin ≥9g/dl; Serum albumin ≥3g/dl

Kidney function

Serum creatinine ≤ 1.5 times the upper limit of normal value, creatinine clearance ≥60 ml/min

Liver function

Bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST ≤ 2 times the upper limit of normal value

The functional indicators of vital organs meet the following requirements ... Neutrophils ≥1.5*10^9/L; Platelet ≥80*10^9/L; Hemoglobin ≥9g/dl; Serum albumin ≥3g/dl; ... Bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST≤ 2 times the upper limit of normal value; ... Serum creatinine ≤ 1.5 times the upper limit of normal value, creatinine clearance ≥60 ml/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify